Vir Biotechnology
Vir Biotechnology raises $250M Series E at $3.3B valuation
Quick Facts
Vir Biotechnology: Series E Funding Round
Vir Biotechnology has successfully raised $250M in Series E funding, reaching a valuation of $3.3B.
Company Overview
Infectious disease treatment development
Funding Details
The Series E round was led by SoftBank Vision Fund, with participation from Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.
Company Information
- Headquarters: 499 Illinois Street, San Francisco, CA 94158
- Founded: 2016
- Employees: 500+
- Category: Biotech
Investment
Vir Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series E
- Arch Venture Partners: Verified investor in Series E
- ARCH Venture Partners: Verified investor in Series E
- Intermediate Capital Group: Verified investor in Series E
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...